
AstraZeneca Pharma India has gained CDSCO approval to import 'Palivizumab,' a crucial therapy to combat Respiratory Syncytial Virus (RSV). The WHO estimates that RSV is responsible for over 60% of acute respiratory infections in children and more than 80% in infants under one year old. Palivizumab is designed to prevent severe lower respiratory tract diseases in high-risk children, including those born prematurely or with congenital heart disease.
Like
Save
Share